Author

Zahi Ibrahim Mitri

Observed names: Mitri Zahi, Mitri, Zahi, Mitri, Zahi I, Mitri, Zahi I., Z Mitri, Z. Mitri, Zahi I Mitri, Zahi I. Mitri, Zahi Mitri

Institutions: BC Cancer Agency, University of British Columbia

Observed institutions: BC Cancer Agency, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of British Columbia, Emory University, Oregon Health & Science University, Baylor College of Medicine, Winship Cancer Institute, OHSU Knight Cancer Institute, American University of Beirut

ORCID: 0000-0001-8765-7723

Observed ORCID: 0000-0001-8765-7723

OpenAlex ID: A5070623583

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

2012 · Zahi Mitri, Tina Constantine, et al. · Chemotherapy Research and Practice · 519

PDF

MITI minimum information guidelines for highly multiplexed tissue images

2022 · Denis Schapiro, Clarence Yapp, et al. · Nature Methods · 85

PDF

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

2015 · Zahi Mitri, Cansu Karakas, et al. · Investigational New Drugs · 82

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

2023 · R. C. Coombes, Sacha Howell, et al. · Nature Communications · 69

PDF

CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice

2021 · Malinda T. West, Claire E. Smith, et al. · European Journal Of Haematology · 60

Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

2020 · Madeline M. Cook, Luai Al Rabadi, et al. · The Oncologist · 57

PDF

A randomized-controlled trial comparing supervised aerobic training to resistance training followed by unsupervised exercise on physical functioning in older breast cancer survivors

2021 · Kerri M. Winters-Stone, Britta Torgrimson-Ojerio, et al. · Journal of Geriatric Oncology · 53

An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer

2022 · Brett E. Johnson, Allison L. Creason, et al. · Cell Reports Medicine · 52

PDF

Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?

2021 · Kerri M. Winters-Stone, Cassie Boisvert, et al. · Supportive Care in Cancer · 50

PDF

Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics

2021 · Allen Li, Jamie M. Keck, et al. · npj Precision Oncology · 50

PDF

Implementing a comprehensive translational oncology platform: from molecular testing to actionability

2018 · Zahi I. Mitri, Swapnil Parmar, et al. · Journal of Translational Medicine · 45

PDF

Impact of TP53 mutations in Triple Negative Breast Cancer

2022 · Zahi I. Mitri, Nour Abuhadra, et al. · npj Precision Oncology · 42

PDF

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

2016 · Zahi Mitri, Rita Nanda, et al. · Clinical Cancer Research · 39

Influence ofCYP2C9andVKORC1Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People

2010 · Maria O. Esmerian, Zahi Mitri, et al. · The Journal of Clinical Pharmacology · 35

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies

2021 · Marilyne Labrie, Allen Li, et al. · npj Precision Oncology · 30

PDF

Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma

2013 · Zahi Mitri, Momin T. Siddiqui, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 29

Genomic Alteration in Metastatic Breast Cancer and Its Treatment

2020 · Allen Li, Stephen M. Schleicher, et al. · American Society of Clinical Oncology Educational Book · 26

Association between Gut Microbiota and Breast Cancer: Diet as a Potential Modulating Factor

2023 · Duygu Altinok Dindar, Brie Chun, et al. · Nutrients · 24

PDF

Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study

2022 · Rajat Thawani, Lina Gao, et al. · BMC Medical Imaging · 20

PDF

Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

2022 · Manish Patel, Carlos Alemany, et al. · Cancer Research · 19

Study protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer

2021 · Kerri M. Winters-Stone, Karen S. Lyons, et al. · Trials · 19

PDF

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer

2023 · Malinda T West, Shaun M Goodyear, et al. · The Oncologist · 18

PDF

Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies.

2019 · Madeline Cook, Luai Al Rabadi, et al. · Journal of Clinical Oncology · 17

Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance

2019 · Marilyne Labrie, Yong Fang, et al. · Advances in experimental medicine and biology · 17

Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.

2021 · Amy Jo Chien, Hatem Hussein Soliman, et al. · Journal of Clinical Oncology · 16

Works count: 96

Citation count: 1,666

H-index: 19

I10-index: 31